Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide

References

• Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81. doi:10.1111/j.1478-3231.2008.01934.x
   Web of Science ®Google Scholar
• Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–S68. doi:10.1016/j.jhep.2014.07.01225443346
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–1127. doi:10.1056/NEJMra100168321992124
   PubMed Web of Science ®Google Scholar
• Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013;110(10):3991–3996. doi:10.1073/pnas.120311011023431163
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282(5386):103–107. doi:10.1126/science.282.5386.1039756471
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327. doi:10.1002/hep.2674424115039
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–2593. doi:10.1001/jama.2012.14487823268517
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355. doi:10.7326/0003-4819-140-5-200403020-0001014996676
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352(25):2609–2617. doi:10.1056/NEJMoa04260815972867
   PubMed Web of Science ®Google Scholar
• Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One. 2009;4(8):e6579. doi:10.1371/journal.pone.000657919668364
   PubMed Web of Science ®Google Scholar
• Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36 Suppl 1:47–57. doi:10.1111/liv.1302726725897
   PubMed Web of Science ®Google Scholar
• McCown MF, Rajyaguru S, Kular S, Cammack N, Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother. 2009;53(5):2129–2132. doi:10.1128/AAC.01598-0819273674
   PubMed Web of Science ®Google Scholar
• Cento V, Mirabelli C, Salpini R, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One. 2012;7(7):e39652. doi:10.1371/journal.pone.003965222792183
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology. 2011;53(5):1742–1751. doi:10.1002/hep.2426221374691
   PubMed Web of Science ®Google Scholar
• McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58(3):902–911. doi:10.1002/hep.2638823504694
   PubMed Web of Science ®Google Scholar
• Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58(4):646–654. doi:10.1016/j.jhep.2012.11.01223178977
   PubMed Web of Science ®Google Scholar
• Komatsu TE, Boyd S, Sherwat A, et al. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology. 2017;152(3):586–597. doi:10.1053/j.gastro.2016.10.01727773808
   PubMed Web of Science ®Google Scholar
• Ji F, Wei B, Yeo YH, et al. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther. 2018;47(5):550–562. doi:10.1111/apt.1450729327780
   PubMed Web of Science ®Google Scholar
• Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954. doi:10.1002/hep.2795026111063
   PubMed Web of Science ®Google Scholar
• European Association for Study of L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236. doi:10.1016/j.jhep.2015.03.02525911336
   PubMed Web of Science ®Google Scholar
• Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87(3):1544–1553. doi:10.1128/JVI.02294-1223152524
   PubMed Web of Science ®Google Scholar
• Paolucci S, Fiorina L, Mariani B, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J. 2013;10:355. doi:10.1186/1743-422X-10-35524341898
   PubMed Web of Science ®Google Scholar
• Costantino A, Spada E, Equestre M, et al. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naive patients with chronic hepatitis C. Virol J. 2015;12:186. doi:10.1186/s12985-015-0414-126577836
   PubMed Web of Science ®Google Scholar
• Wang Y, Rao HY, Xie XW, et al. Direct-acting antiviral agents resistance-associated polymorphisms in chinese treatment-naive patients infected with genotype 1b hepatitis C virus. Chin Med J (Engl). 2015;128(19):2625–2631. doi:10.4103/0366-6999.16603826415801
   PubMed Web of Science ®Google Scholar
• Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naive hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist. 2017;10:377–392. doi:10.2147/IDR.S14659529184422
   PubMed Web of Science ®Google Scholar
• Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310. doi:10.1038/srep2031026842909
   PubMed Web of Science ®Google Scholar
• Kliemann DA, Tovo CV, Da Veiga AB, de Mattos AA, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol. 2016;22(40):8910–8917. doi:10.3748/wjg.v22.i40.891027833382
   PubMed Web of Science ®Google Scholar
• Patino-Galindo JA, Salvatierra K, Gonzalez-Candelas F, López-Labrador FX. Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother. 2016;60(4):2402–2416. doi:10.1128/AAC.02776-1526856832
   PubMed Web of Science ®Google Scholar
• Welzel TM, Bhardwaj N, Hedskog C, et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol. 2017;67(2):224–236. doi:10.1016/j.jhep.2017.03.01428343981
   PubMed Web of Science ®Google Scholar
• Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat. 2018;37:17–39. doi:10.1016/j.drup.2018.01.00429525636
   PubMed Web of Science ®Google Scholar
• Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504. doi:10.1016/j.jhep.2015.09.01126409317
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70–86. doi:10.1053/j.gastro.2016.04.00327080301
   PubMed Web of Science ®Google Scholar
• Ng TI, Tripathi R, Reisch T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother. 2018;62(1):e01620–17.29084747
   PubMed Web of Science ®Google Scholar
• Wing PAC, Jones M, Cheung M, et al. Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir. Gastroenterology. 2019;157:692–704.e9. doi:10.1053/j.gastro.2019.05.00731078622
   PubMed Web of Science ®Google Scholar
• McPhee F, Ueland J, Vellucci V, et al. Impact of preexisting hepatitis C virus genotype 6 NS3, NS5A, and NS5B polymorphisms on the in vitro potency of direct-acting antiviral agents. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.00779-19
   Web of Science ®Google Scholar
• Cheng G, Tian Y, Doehle B, et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother. 2016;60(3):1847–1853. doi:10.1128/AAC.02524-1526824950
   PubMed Web of Science ®Google Scholar
• Dvory-Sobol H, Han B, Lu J, et al. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6. J Viral Hepat. 2019;26(8):991–1001. doi:10.1111/jvh.1311631009123
   PubMed Web of Science ®Google Scholar
• Han B, Parhy B, Zhou E, et al. In vitro susceptibility of hepatitis C virus genotype 1 through 6 clinical isolates to the pangenotypic NS3/4A inhibitor voxilaprevir. J Clin Microbiol. 2019;57(4). doi:10.1128/JCM.01844-18
   Web of Science ®Google Scholar
• Sano T, Akuta N, Suzuki F, et al. Role of NS5A-L31/Y93 double wild-type in failure of glecaprevir/pibrentasvir double therapy in two patients with a history of direct-acting antiviral agent failure: an ultra-deep sequencing analysis. Intern Med. 2019. doi:10.2169/internalmedicine.2604-18
   Web of Science ®Google Scholar
• Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083–2091. doi:10.1002/hep.2711324604476
   PubMed Web of Science ®Google Scholar
• Harrington PR, Komatsu TE, Deming DJ, et al. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives. Hepatology. 2018;67(6):2430–2448. doi:10.1002/hep.2969329194682
   PubMed Web of Science ®Google Scholar
• Xue W, Pan D, Yang Y, Liu H, Yao X. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. Antiviral Res. 2012;93(1):126–137. doi:10.1016/j.antiviral.2011.11.00722127068
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Hall N, Sheerin D, Carr M, De Gascun CF. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. Antivir Ther. 2016;21(5):447–453. doi:10.3851/IMP302526789637
   PubMed Web of Science ®Google Scholar
• Wu R, Chi X, Wang X, et al. IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection. Infect Genet Evol. 2016;39:132–140. doi:10.1016/j.meegid.2016.01.02026820907
   PubMed Web of Science ®Google Scholar
• Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57(1):13–18. doi:10.1016/j.jcv.2012.12.02023384816
   PubMed Web of Science ®Google Scholar
• Peiffer KH, Sommer L, Susser S, et al. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology. 2016;63(1):63–73. doi:10.1002/hep.2825526406534
   PubMed Web of Science ®Google Scholar
• Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63(5):1430–1441. doi:10.1002/hep.2847326822022
   PubMed Web of Science ®Google Scholar
• Bartolini B, Giombini E, Taibi C, et al. Characterization of naturally occurring NS5A and NS5B polymorphisms in patients infected with HCV genotype 3a treated with direct-acting antiviral agents. Viruses. 2017;9(8):212. doi:10.3390/v9080212
   Web of Science ®Google Scholar
• Walker A, Filke S, Lubke N, et al. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure. Virol J. 2017;14(1):106. doi:10.1186/s12985-017-0779-428595606
   PubMed Web of Science ®Google Scholar
• Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59(12):1666–1674. doi:10.1093/cid/ciu69725266287
   PubMed Web of Science ®Google Scholar
• Donaldson EF, Harrington PR, O’Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61(1):56–65. doi:10.1002/hep.2737525123381
   PubMed Web of Science ®Google Scholar
• Hedskog C, Dvory-Sobol H, Gontcharova V, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015;22(11):871–881. doi:10.1111/jvh.1240525784085
   PubMed Web of Science ®Google Scholar
• Peres-da-Silva A, Brandao-Mello CE, Lampe E. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV. Antivir Ther. 2017;22(5):447–451. doi:10.3851/IMP313128085003
   PubMed Web of Science ®Google Scholar
• Di Maio VC, Cento V, Lenci I, et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37(4):514–528. doi:10.1111/liv.1332728105744
   PubMed Web of Science ®Google Scholar
• Ito J, Suda G, Yamamoto Y, et al. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. Hepatol Res. 2016;46(13):1294–1303. doi:10.1111/hepr.1268526896756
   PubMed Web of Science ®Google Scholar
• Dietz J, Susser S, Vermehren J, et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology. 2018;154(4):976–988.e4. doi:10.1053/j.gastro.2017.11.00729146520
   PubMed Web of Science ®Google Scholar